EMEA-003241-PIP01-22-M01 - paediatric investigation plan
osivelotor
PIPHuman
Key facts
- Active substance
- osivelotor
- Therapeutic area
- Congenital, familial and genetic disorders
- Decision number
- P/0302/2024
- PIP number
- EMEA-003241-PIP01-22-M01
- Pharmaceutical form(s)
- Age appropriate oral solid dosage form
- Tablet
- Condition(s) / indication(s)
- Treatment of sickle cell disease
- Route(s) of administration
- Oral use
- Contact for public enquiries
Pfizer Europe MA EEIG
E-mail: medical.information@pfizer.com
Tel: +44 (0)1304 616161- Decision type
- PM: decision on the application for modification of an agreed PIP
- Decision date